EGI
NXTC icon

EAM Global Investors’s NextCure NXTC Stock Holding History

EAM Global Investors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,091
Closed -$930K – 140
2020
Q1 		$930K Sell
2,091
-1,389
-40% -$742K 0.54% 89
2019
Q4 		$2.35M Sell
3,480
-942
-21% -$473K 0.94% 29
2019
Q3 		$1.64M Buy
+4,422
New +$1.44M 0.8% 56

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Global Investors's NXTC Position: Q2 2020 in Review

EAM Global Investors sold out of NextCure (NXTC) in Q2 2020, closing a stake of 2,091 shares — an estimated $930K sold.

EAM Global Investors first reported a position in NXTC in Q3 2019 and held it in 3 quarters. The position peaked at $2.35M in Q4 2019. 88 funds tracked by Wall St. Rank hold NXTC as of Q2 2020.

  • EAM Global Investors reported no remaining NextCure position as of Q2 2020 after selling out during the quarter.
  • EAM Global Investors sold 2,091 NextCure shares in Q2 2020, an estimated $930K.
  • EAM Global Investors first reported a position in NextCure in Q3 2019 and held it in 3 quarters.
  • EAM Global Investors's NextCure position peaked at $2.35M in Q4 2019.
  • 88 funds tracked by Wall St. Rank held NextCure as of Q2 2020.

Based on EAM Global Investors's 13F filing for Q2 2020, filed 13 Aug 2020.